SCHEMBL534483

SCHEMBL534483

FC(F)Oc1ccccc1-c1cc[c]cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.58
KCNN4 O15554 4/20 0.40
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
ADRA2A P08913 6/20 0.35
ADRA2B P18089 6/20 0.35
ADRA2C P18825 6/20 0.35
HRH1 P35367 1/20 0.34
KMT2A Q03164 1/20 0.34
MAOA P21397 3/20 0.34
MAOB P27338 3/20 0.34
NISCH Q9Y2I1 1/20 0.34
TNF P01375 1/20 0.34
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27602279 0.84 DRD1 (0.66) DRD1KCNN4KDM4EALDH1A1ADRA2A
SCHEMBL695611 0.81 ADRA2A (0.41) DRD1KCNN4ALDH1A1ADRA2AADRA2B
SCHEMBL8802236 0.80 DRD1 (0.45) DRD1KCNN4KDM4EALDH1A1KMT2A
SCHEMBL16719972 0.75 DRD1 (0.41) DRD1KCNN4KDM4EALDH1A1ADRA2A
SCHEMBL533511 0.75 APP (0.48) KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL699801 0.74 FFAR4 (0.47) KCNN4KDM4EALDH1A1
SCHEMBL7683329 0.74 DRD1 (0.43) DRD1HTTSMN1; SMN2
SCHEMBL8802231 0.73 DRD1 (0.45) DRD1KCNN4KDM4EALDH1A1KMT2A
SCHEMBL5329495 0.73 DRD1 (0.45) DRD1KCNN4KDM4EALDH1A1KMT2A
SCHEMBL7678739 0.73 KCNN4 (0.45) DRD1KCNN4KDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 EP disclosed
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE INDUSTRIES, LTD. (JP) 2014-04-24 US disclosed
US-8648097-B2 Pyridylaminoacetic acid compound UBE INDUSTRIES, LTD. (JP) 2014-02-11 US disclosed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US disclosed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP disclosed
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE CORPORATION (JP) 2011-03-03 US disclosed
EP-2264009-A1 PYRIDYLAMINOACETIC ACID COMPOUND Ube Industries, Ltd. (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 DRD1 1575/4885KCNN4 789/4885KDM4E 2779/4885
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 DRD1 1851/4885KCNN4 749/4885KDM4E 2804/4885
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 DRD1 3015/4885KCNN4 1598/4885KDM4E 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.